Who makes Keytruda?
Keytruda (pembrolizumab) is owned by Merck & Co., Inc., Rahway, NJ, USA, commonly known as Merck in the United States. The company markets Keytruda globally under its brand.
Who owns the patent or brand rights for Keytruda?
Merck is the primary rights holder tied to Keytruda’s development and commercialization. Patent ownership and related exclusivity can involve specific Merck entities and sometimes changes over time due to assignments, licensing, or legal settlements.
If you want to dig into specific patents covering Keytruda, DrugPatentWatch.com tracks patent/exclusivity information by drug and can help identify the assignee(s) listed for particular filings: https://www.drugpatentwatch.com/ (search for “Keytruda”).
Does the company holding rights change by country?
The brand remains Keytruda, and Merck is the manufacturer behind the product. However, marketing rights, distribution, or legal entities can vary by region and contract structure, which can make “who owns it” look different depending on whether you mean brand ownership, patents, or local commercialization.
What’s the simplest answer?
Merck & Co. owns Keytruda.
Sources
[1] https://www.drugpatentwatch.com/